TL;DR
Researchers have developed "blood-imbibing and -crosslinking microparticles" (BICMs) that stop severe bleeding in under 30 seconds by turning blood itself into a structural adhesive. By physically sucking blood into their pores and chemically bonding with blood proteins, these microparticles form "fortified clots" that resist rebleeding even under high blood pressure or in patients with impaired natural coagulation.
What Problem Does This Paper Address?
Natural blood clotting is a slow, multi-stage process that can take 6 to 10 minutes to form a stable, covalently crosslinked seal. In cases of massive trauma or "coagulopathy" (where the body’s ability to clot is impaired), this delay is often fatal.
Current solutions have significant drawbacks:
- Topical Hemostats: Most (like sponges or powders) simply accelerate the natural process but don't provide immediate structural strength.
- Tissue Adhesives: While strong, these "glues" are often hampered by the very blood they are trying to stop; the fluid layer prevents the glue from reaching and bonding with the underlying tissue.
- Rebleeding: Even if a clot forms, it often fails when a patient’s blood pressure is restored during medical resuscitation, leading to secondary hemorrhage.
The authors sought a "coagulation-independent" way to create a high-strength seal that works with blood rather than being blocked by it.
Methods
The team engineered microparticles based on hyaluronic acid (HA), a biocompatible polymer already widely used in medicine.
- Imbibition (Sucking): The particles are pre-crosslinked to create a porous network. Through capillary action, they "imbibe" (drink) surrounding blood, pulling it into the particle's internal microchannels.
- Covalent Chemistry: The surfaces of these particles are grafted with o-phthalaldehyde (OPA) groups. Unlike common reactive groups (like NHS esters) that degrade quickly in water, OPA is stable in aqueous environments but reacts rapidly with primary amines found on blood proteins and the tissue matrix.
- Fortified Clot Formation: Once the blood is sucked in, the OPA groups create covalent bonds between the particles, the blood proteins, and the wound site. This creates a composite material—a "fortified clot"—that forms independently of the body's natural enzymatic clotting cascade.
The researchers used rheological testing to measure clot stiffness, atomic force microscopy (AFM) to probe the interface strength, and various animal models to test real-world efficacy.
Datasets
As a materials science and bioengineering study, the "datasets" consist of experimental results across several animal models designed to mimic clinical emergencies:
- Rat Liver Volumetric Defect: Used to measure initial hemostasis time and total blood loss.
- Coagulopathic Porcine (Pig) Liver Injury: A "stress test" where the pig's blood was diluted to impair natural clotting, mimicking a trauma patient who has received massive fluid transfusions.
- Rabbit Femoral Artery Injury: A rebleeding model where blood pressure was intentionally raised (fluid resuscitation) after the initial clot formed to see if the seal would hold.
- Comparative Benchmarking: The BICMs were tested against several FDA-approved standards, including Arista, Surgicel, Avitene, Celox, Quikclot, and Gelfoam + Thrombin.
Key Insights and Ideas
- Blood as a Structural Asset: Instead of trying to repel blood to reach the tissue, BICMs treat blood as a reactive building block. The blood becomes the "mortar" between the microparticle "bricks."
- Superior Chemistry: The choice of OPA groups is critical. The authors show that OPA achieves 100% conversion with amines within 60 minutes and remains stable for over 30 days in saline, whereas standard reactive esters lose most of their activity within hours.
- Mechanical Reinforcement: The resulting fortified clot has a storage modulus (stiffness) roughly 100 times higher than a natural blood clot.
- Automatic Mixing: Because the particles use capillary suction to pull in blood, they don't require the manual "mixing" or "pressure" typically needed for surgical glues. They work "automatically" upon contact.
Key Results
- Speed: BICMs achieved hemostasis in less than 30 seconds across all models.
- Blood Loss: In the rat model, BICMs limited blood loss to ~35 mg (compared to ~100–300 mg for commercial hemostats). In the challenging pig model, blood loss was only ~1 g (compared to ~7.6 g for Surgicel).
- Rebleeding Prevention: In the rabbit model, only 4% of the BICM group experienced rebleeding when blood pressure was raised, whereas 32% to 51% of the commercial hemostat groups failed.
- Biocompatibility: The particles showed no cytotoxicity and were gradually biodegraded by the body over three months, with histological evidence showing normal tissue healing.
Limitations and Future Work
- Particle Geometry: The authors acknowledge that the shape and size uniformity of the microparticles (currently produced via fragmentation) could be optimized. Irregular shapes might increase the risk of unpredictable embolization (particles traveling elsewhere in the bloodstream).
- Delivery Systems: While the paper mentions potential use via endoscopes, further engineering is needed to develop specialized applicators for minimally invasive surgery.
- Clinical Translation: While the 3-month porcine and rat data are promising, moving to human trials will require rigorous manufacturing scaling and long-term safety profiles regarding the OPA-amine reaction products.
Reference: Chen, T., et al. "Covalently reactive microparticles imbibe blood to form fortified clots for rapid hemostasis and prevention of rebleeding." Nature Communications (2025).
Summary updated